What is the value of AbbVie's acquisition of Apogee?

The deal is valued at $10.9 billion in cash.

Why is AbbVie acquiring Apogee?

To strengthen its immunology pipeline after Humira's patent expiration and leverage Apogee's promising respiratory treatments.

When is the AbbVie-Apogee deal expected to close?

In the first half of 2026, pending regulatory approvals.

Market Movers: AbbVie to Acquire Apogee for $10.9B, Coca-Cola Faces IRS in Appeals Court

Q: What is the dispute between Coca-Cola and the IRS?

The IRS alleges Coca-Cola used improper transfer pricing to reduce its tax liability, potentially costing billions.

AbbVie announced a $10.9 billion acquisition of Apogee Therapeutics, while Coca-Cola faces the IRS in an appeals court over a tax dispute. Full details on both stories.

U.S. markets saw two major developments on Monday: AbbVie (ABBV) acquiring Apogee Therapeutics (APGE) in a $10.9 billion deal, and Coca-Cola (KO) continuing its legal battle with the Internal Revenue Service (IRS) in an appeals court.

AbbVie's Acquisition of Apogee

AbbVie announced it will acquire Apogee Therapeutics in an all-cash deal valued at $10.9 billion. The acquisition aims to strengthen AbbVie's pipeline in immunology and respiratory diseases, as Apogee develops promising treatments for asthma and atopic dermatitis.

Deal Terms

Total Value: $10.9 billion in cash.
Price per Share: Not yet disclosed.
Premium: Not specified.
Expected Close: First half of 2026, subject to regulatory approvals.

Rationale

AbbVie seeks to bolster its immunology portfolio after the Humira patent expiration. Apogee's innovative therapies are seen as a strategic fit.

Regulatory Challenges

The deal is expected to undergo FTC antitrust review, but analysts do not foresee major obstacles.

Coca-Cola vs. IRS

Separately, Coca-Cola is facing the IRS in an appeals court over a long-standing tax dispute. The IRS alleges that Coca-Cola used improper transfer pricing to reduce its tax liability, potentially costing the company billions.

Case Details

Plaintiff: Internal Revenue Service (IRS).
Company: Coca-Cola (KO).
Disputed Amount: Not disclosed, but previous estimates suggest $3.3 billion.
Current Status: Appeal after a prior ruling in Coca-Cola's favor.

Company's Position

Coca-Cola maintains that its tax practices are legal and compliant with international laws. It views the prior ruling as validation of its position.

What This Means for Investors

The AbbVie deal reflects continued M&A activity in the pharmaceutical sector, potentially boosting investor confidence. The Coca-Cola case represents a legal risk that could impact future earnings if the ruling goes against the company.